All-in-one AAV-delivered epigenome-editing platform: proof-of-concept and therapeutic implications for neurodegenerative disorders.

IF 3.1 3区 物理与天体物理 Q2 PHYSICS, APPLIED
Boris Kantor, Bernadette Odonovan, Joseph Rittiner, Dellila Hodgson, Nicholas Lindner, Sophia Guerrero, Wendy Dong, Austin Zhang, Ornit Chiba-Falek
{"title":"All-in-one AAV-delivered epigenome-editing platform: <i>proof-of-concept</i> and therapeutic implications for neurodegenerative disorders.","authors":"Boris Kantor, Bernadette Odonovan, Joseph Rittiner, Dellila Hodgson, Nicholas Lindner, Sophia Guerrero, Wendy Dong, Austin Zhang, Ornit Chiba-Falek","doi":"10.1101/2023.04.14.536951","DOIUrl":null,"url":null,"abstract":"<p><p>Safely and efficiently controlling gene expression is a long-standing goal of biomedical research, and the recently discovered bacterial CRISPR/Cas system can be harnessed to create powerful tools for epigenetic editing. Current state-of-the-art systems consist of a deactivated-Cas9 nuclease (dCas9) fused to one of several epigenetic effector motifs/domains, along with a guide RNA (gRNA) which defines the genomic target. Such systems have been used to safely and effectively silence or activate a specific gene target under a variety of circumstances. Adeno-associated vectors (AAVs) are the therapeutic platform of choice for the delivery of genetic cargo; however, their small packaging capacity is not suitable for delivery of large constructs, which includes most CRISPR/dCas9-effector systems. To circumvent this, many AAV-based CRISPR/Cas tools are delivered in two pieces, from two separate viral cassettes. However, this approach requires higher viral payloads and usually is less efficient. Here we develop a compact dCas9-based repressor system packaged within a single, optimized AAV vector. The system uses a smaller dCas9 variant derived from <i>Staphylococcus aureus</i> ( <i>Sa</i> ). A novel repressor was engineered by fusing the small transcription repression domain (TRD) from MeCP2 with the KRAB repression domain. The final d <i>Sa</i> Cas9-KRAB-MeCP2(TRD) construct can be efficiently packaged, along with its associated gRNA, into AAV particles. Using reporter assays, we demonstrate that the platform is capable of robustly and sustainably repressing the expression of multiple genes-of-interest, both <i>in vitro</i> and <i>in vivo</i> . Moreover, we successfully reduced the expression of ApoE, the stronger genetic risk factor for late onset Alzheimer's disease (LOAD). This new platform will broaden the CRISPR/dCas9 toolset available for transcriptional manipulation of gene expression in research and therapeutic settings.</p>","PeriodicalId":16789,"journal":{"name":"Journal of Physics D: Applied Physics","volume":"21 1","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2024-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11118458/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Physics D: Applied Physics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2023.04.14.536951","RegionNum":3,"RegionCategory":"物理与天体物理","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHYSICS, APPLIED","Score":null,"Total":0}
引用次数: 0

Abstract

Safely and efficiently controlling gene expression is a long-standing goal of biomedical research, and the recently discovered bacterial CRISPR/Cas system can be harnessed to create powerful tools for epigenetic editing. Current state-of-the-art systems consist of a deactivated-Cas9 nuclease (dCas9) fused to one of several epigenetic effector motifs/domains, along with a guide RNA (gRNA) which defines the genomic target. Such systems have been used to safely and effectively silence or activate a specific gene target under a variety of circumstances. Adeno-associated vectors (AAVs) are the therapeutic platform of choice for the delivery of genetic cargo; however, their small packaging capacity is not suitable for delivery of large constructs, which includes most CRISPR/dCas9-effector systems. To circumvent this, many AAV-based CRISPR/Cas tools are delivered in two pieces, from two separate viral cassettes. However, this approach requires higher viral payloads and usually is less efficient. Here we develop a compact dCas9-based repressor system packaged within a single, optimized AAV vector. The system uses a smaller dCas9 variant derived from Staphylococcus aureus ( Sa ). A novel repressor was engineered by fusing the small transcription repression domain (TRD) from MeCP2 with the KRAB repression domain. The final d Sa Cas9-KRAB-MeCP2(TRD) construct can be efficiently packaged, along with its associated gRNA, into AAV particles. Using reporter assays, we demonstrate that the platform is capable of robustly and sustainably repressing the expression of multiple genes-of-interest, both in vitro and in vivo . Moreover, we successfully reduced the expression of ApoE, the stronger genetic risk factor for late onset Alzheimer's disease (LOAD). This new platform will broaden the CRISPR/dCas9 toolset available for transcriptional manipulation of gene expression in research and therapeutic settings.

一体化 AAV 表观基因组编辑平台:概念验证及对神经退行性疾病的治疗意义。
安全有效地控制基因表达是生物医学研究的一个长期目标,最近发现的细菌 CRISPR/Cas 系统可以用来创建强大的表观遗传编辑工具。目前最先进的系统由融合了几种表观遗传效应基团/域之一的去活化 Cas9 核酸酶(dCas9)和确定基因组靶点的引导 RNA(gRNA)组成。这种系统已被用于在各种情况下安全有效地沉默或激活特定基因靶点。腺相关载体(AAV)是递送基因货物的首选治疗平台,但其包装容量小,不适合递送大型构建物,其中包括大多数 CRISPR/dCas9 效应器系统。为了规避这一问题,许多基于 AAV 的 CRISPR/Cas 工具都是由两个独立的病毒盒分两部分递送的。然而,这种方法对病毒载荷的要求较高,效率通常也较低。在这里,我们开发了一种基于 dCas9 的紧凑型抑制剂系统,将其包装在单一的优化 AAV 载体中。该系统使用了源自金黄色葡萄球菌(Sa)的较小的 dCas9 变体。通过将 MeCP2 的小转录抑制结构域(TRD)与 KRAB 抑制结构域融合,设计出了一种新型抑制器。最终d Sa Cas9-KRAB-MeCP2(TRD)构建体可以连同其相关的gRNA一起被有效地包装到AAV颗粒中。通过报告实验,我们证明该平台能够在体外和体内稳健、持续地抑制多个相关基因的表达。此外,我们还成功减少了载脂蛋白E的表达,而载脂蛋白E是晚发性阿尔茨海默病(LOAD)的强遗传风险因子。这一新平台将拓宽 CRISPR/dCas9 工具集的使用范围,使其能够在研究和治疗环境中对基因表达进行转录操作。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Physics D: Applied Physics
Journal of Physics D: Applied Physics 物理-物理:应用
CiteScore
6.80
自引率
8.80%
发文量
835
审稿时长
2.1 months
期刊介绍: This journal is concerned with all aspects of applied physics research, from biophysics, magnetism, plasmas and semiconductors to the structure and properties of matter.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信